Stock OPTN OPTINOSE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages OptiNose, Inc.

Equities

OPTN

US68404V1008

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
1.13 USD -3.42% Intraday chart for OptiNose, Inc. +9.71% -12.40%
05-14 Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M MT
05-09 OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025
Sector Update: Health Care Stocks Steady Premarket Monday
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023
OptiNose Raises Full-Year 2023 Xhance Net Revenue Outlook
OptiNose, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
OptiNose, Inc. Approves Board Changes
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Optinose, Inc. Provides Revenue Guidance for Full Year of 2023
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OPTN Stock
  4. News OptiNose, Inc.
  5. Other languages